Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
1998
Background:Only 15–20% of patients with chronic hepatitis C achieve a sustained virological response with interferon therapy. The aim of this study was to compare the efficacy and safety of interferon α2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection wi
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
1
References
43
Citations
NaN
KQI